Blue Water Vaccines Announces Appointment of Vuk Jeremić, Previous Chair of the Council of Europe’s Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors
09 November 2022 - 12:30AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the
“Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced the appointment of seasoned advisor and executive, Vuk
Jeremić, to the Company’s board of directors.
Mr. Jeremić brings decades of experience in operational and
strategy advisement on a global scale for both private and public
companies. Currently, Mr. Jeremić is the President of the Center
for International Relations and Sustainable Development (CIRSD), a
global public policy think-tank, and Editor-in-Chief of the
quarterly magazine “Horizons – Journal of International Relations
and Sustainable Development.” Since 2013, Mr. Jeremić has operated
Vuk Jeremić ent Consulting Agency Belgrade, through which he
currently serves as a senior advisor to a leading global private
equity firm and to one of the largest cryptocurrency exchanges. He
also serves on the Advisory Board of the NYSE-listed technology
special purpose acquisition company, Adit Edtech Acquisition Corp.
(ADEX:U). In addition, he has lectured around the world at major
universities, think-tanks, and institutes, as well as published
opinion pieces in leading outlets including The New York Times, The
Washington Post, The Wall Street Journal, The Financial Times, and
Le Monde.
Prior to his experience in company advisement, Mr. Jeremić held
multiple key positions in global public policy development
nationally and internationally. In 2007, he chaired the Council of
Europe’s Committee of Ministers and, from 2007 to 2012, he served
as Serbia’s Minister of Foreign Affairs. In June 2012, Mr. Jeremić
was directly elected by the majority of world’s nations to be the
President of the 67th session of the United Nations (UN) General
Assembly. During his term in office, he played a leading role in
steering the UN towards the establishment of the Sustainable
Development Goals (SDGs).
“With his impressive resume both in operational advisement and
global public policy development, we are thrilled to welcome Mr.
Jeremić to our board,” said Joseph Hernandez, Chairman and Chief
Executive Officer of Blue Water Vaccines. “We are confident he will
bring a fresh perspective and new ideas to Blue Water Vaccines as
we continue to grow the Company and progress our vaccine candidates
towards commercialization.”
Mr. Jeremić holds a bachelor’s degree in Theoretical and
Experimental Physics from Cambridge University and a master’s
degree in Public Administration in International Development from
Harvard University’s John F. Kennedy School of Government.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
Company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical
Center, and St. Jude Children's Hospital. The Company is developing
a universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s
Registration Statement on Form S-1, filed with the Securities and
Exchange Commission (the “SEC”) on August 29, 2022 and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Media Contact Information:Blue Water Media RelationsTelephone:
(646) 942-5591Email: Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2023 to Aug 2024